Analytical Validation of PGDx elio™ Plasma Focus Dx to Facilitate Precision Oncology Through Decentralized Liquid Biopsy for Solid Tumor Profiling

The PGDx elio™ Plasma Focus Dx is a highly specific, sensitive, reproducible, and accurate hybrid capture-based next-generation sequencing (NGS) assay optimized for cell-free DNA with excellent performance in analytical validation studies across various variant types and solid tumor types. These results support the use of PGDx elio Plasma Focus Dx as a decentralized liquid biopsy solution for informing precision oncology decision-making.